Posted by Michael Wonder on 24 Jun 2021
PMPRB risks harming the health of Canadians by reducing access to new medicines
23 June 2021 - On June 21, Innovative Medicines Canada submitted six recommendations to the federal government as part of the Patented Medicine Prices Review Board’s Guideline Monitoring and Evaluation Plan consultations.
Innovative Medicines Canada firmly maintains that industry is prepared to consult and collaborate with governments with a view to protecting the health of Canadians.
